Gary G Chiang

List of Publications by Citations

35	4,163	25	36
papers	citations	h-index	g-index
36	4,623	7.9	4.95
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
35	Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. *Molecular and Cellular Biology*, **2002**, 22, 7004-14	4.8	995
34	Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. *Journal of Biological Chemistry*, **2005**, 280, 25485-90	5.4	413
33	Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. *Nature*, **2017**, 550, 128-132	50.4	303
32	Targeting the mTOR signaling network in cancer. *Trends in Molecular Medicine*, **2007**, 13, 433-42	11.5	281
31	Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. *Molecular Cell*, **2005**, 19, 607-18	17.6	233
30	Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. *Journal of Biological Chemistry*, **2011**, 286, 42626-42634	5.4	231
29	The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. *Nature Chemical Biology*, **2017**, 13, 389-395	11.7	139
28	Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. *Cancer Research*, **2010**, 70, 3287-98	10.1	133
27	Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 4749-59	3.4	127
26	Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. *ACS Medicinal Chemistry Letters*, **2014**, 5, 205-9	4.3	124
25	The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. *Molecular Cancer Therapeutics*, **2007**, 6, 2505-14	6.1	122
24	Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. *Cancer Research*, **2003**, 63, 8451-60	10.1	119
23	Specific dephosphorylation of the Lck tyrosine protein kinase at Tyr-394 by the SHP-1 protein-tyrosine phosphatase. *Journal of Biological Chemistry*, **2001**, 276, 23173-8	5.4	110
22	REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. *EMBO Reports*, **2009**, 10, 866-72	6.5	103
21	Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition. *Journal of Medicinal Chemistry*, **2018**, 61, 3516-3540	8.3	81
20	Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. *Organic and Biomolecular Chemistry*, **2004**, 2, 1911-20	3.9	77
19	Control of mTORC1 signaling by the Opitz syndrome protein MID1. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 8680-5	11.5	69

18	The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. *Nature Chemical Biology*, **2017**, 13, 317-324	11.7	62
17	Tyrosine phosphorylation of RNA polymerase II carboxyl-terminal domain by the Abl-related gene product. *Journal of Biological Chemistry*, **1997**, 272, 18905-9	5.4	53
16	The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia. *PLoS ONE*, **2015**, 10, e0131716	3.7	50
15	Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. *ACS Medicinal Chemistry Letters*, **2015**, 6, 695-700	4.3	49
14	The role of Dbf4/Drf1-dependent kinase Cdc7 in DNA-damage checkpoint control. *Molecular Cell*, **2008**, 32, 862-9	17.6	41
13	Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. *Journal of Medicinal Chemistry*, **2020**, 63, 5879-5955	8.3	39
12	The FRB domain of mTOR: NMR solution structure and inhibitor design. *Biochemistry*, **2006**, 45, 10294-302	3.2	38
11	Phosphorylation of a Src kinase at the autophosphorylation site in the absence of Src kinase activity. *Journal of Biological Chemistry*, **2000**, 275, 6055-8	5.4	31
10	SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 1576-1583	2.9	23
9	Design, synthesis, and structure-activity relationships of 3-ethynyl-1H-indazoles as inhibitors of the phosphatidylinositol 3-kinase signaling pathway. *Journal of Medicinal Chemistry*, **2010**, 53, 8368-75	8.3	22
8	Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice. *Cancer Research*, **2010**, 70, 8937-47	10.1	16
7	eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL). *Blood*, **2015**, 126, 1554-1554	2.2	16
6	Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A. *Molecular Cancer Therapeutics*, **2021**, 20, 26-36	6.1	16
5	Divergent S phase checkpoint activation arising from prereplicative complex deficiency controls cell survival. *Molecular Biology of the Cell*, **2009**, 20, 3953-64	3.5	15
4	Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-B pathways. *Pigment Cell and Melanoma Research*, **2011**, 24, 703-13	4.5	13
3	Determination of the catalytic activities of mTOR and other members of the phosphoinositide-3-kinase-related kinase family. *Methods in Molecular Biology*, **2004**, 281, 125-41	1.4	11
2	Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors.. *Frontiers in Oncology*, **2021**, 11, 766298	5.3	4
1	mRNA translation is a therapeutic vulnerability necessary for bladder epithelial transformation. *JCI Insight*, **2021**, 6,	9.9	2